Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 11/20 | 0.58 |
| ▸ | WNT3A | P56704 | 8/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695788 | 0.82 | CTNNB1 (0.67) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL22394673 | 0.80 | SMN1; SMN2 (0.61) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL22394706 | 0.78 | CTNNB1 (0.67) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL6794489 | 0.77 | NPC1 (0.59) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL8967686 | 0.75 | KMT2A (0.42) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL12688363 | 0.75 | RAB9A (0.49) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL10027736 | 0.74 | CTNNB1 (1.00) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL15968604 | 0.73 | CTNNB1 (1.00) | CTNNB1WNT3AATMHPGDPKM | |
| SCHEMBL1092875 | 0.73 | ATM (1.00) | CTNNB1WNT3AATMRAB9ANPC1 | |
| SCHEMBL653025 | 0.72 | PKM (0.87) | CTNNB1WNT3AATMHPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| CN-111566099-B | Antibacterial compounds | 迪斯库瓦有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| EP-3704105-A1 | ANTIBACTERIAL COMPOUNDS | Discuva Ltd. (GB) | 2020-09-09 | — | — | EP | disclosed |
| CN-111566099-A | Antibacterial compounds | 迪斯库瓦有限公司 | 2020-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | CTNNB1 4159/4885WNT3A 4202/4885ATM 1979/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | CTNNB1 3726/4885WNT3A 3608/4885ATM 2809/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | CTNNB1 4159/4885WNT3A 4202/4885ATM 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.